Q2 Earnings Estimate for OCUL Issued By HC Wainwright

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – HC Wainwright issued their Q2 2027 EPS estimates for Ocular Therapeutix in a report issued on Thursday, June 18th. HC Wainwright analyst Y. Chen expects that the biopharmaceutical company will post earnings of ($0.38) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q4 2027 earnings at ($0.37) EPS.

OCUL has been the topic of a number of other research reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a report on Wednesday, May 6th. Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Robert W. Baird raised their target price on Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, William Blair restated an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $24.89.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL opened at $9.43 on Monday. The firm has a market capitalization of $2.06 billion, a P/E ratio of -6.46 and a beta of 0.90. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12. The company has a fifty day moving average of $8.99 and a 200 day moving average of $9.90. Ocular Therapeutix has a 52 week low of $6.23 and a 52 week high of $16.44.

Insider Activity at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,156 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the sale, the insider directly owned 2,597,170 shares of the company’s stock, valued at approximately $21,296,794. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 28,999 shares of company stock valued at $237,792. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Ocular Therapeutix

Institutional investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC boosted its position in Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Ocular Therapeutix in the 4th quarter worth approximately $31,000. Hilton Head Capital Partners LLC raised its position in shares of Ocular Therapeutix by 30.4% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,053 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of Ocular Therapeutix in the 4th quarter valued at approximately $61,000. Finally, KBC Group NV purchased a new position in shares of Ocular Therapeutix in the 4th quarter valued at approximately $78,000. 59.21% of the stock is owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.